Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass
NCT01267487 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240
Last updated 2010-12-28
Summary
There are currently several schemes described for anticoagulation with heparin and its reversal with protamine during cardiac surgery with CPB. The oldest, and most used in our routine environment, is the scheme of fixed doses, in which a bolus dose of heparin at the start of CPB is established in IU/kg of body weight and the dose of protamine at the end of CPB is calculated based on the initial dose of heparin administered.
These schemes do not take into account the variability inter-patients and can result in overdose or sub-doses of one or both drugs.
The titration schedule of doses of heparin and protamine through the principle of dose-response curve of Bull promotes individualization of dosage according to the response of each patient. This scheme has been associated with an effective reversal of the effect of heparin after CPB and with reduction of post-operatory bleeding and transfusion.
The restoration of a state of anticoagulation by heparin after its reversal by protamine is called "rebound effect". It is a phenomenon explained by the recirculation of heparin stored in the reticulum-endothelial system and connective tissue, or by free residual concentration of heparin after clearance of protamine. This effect may be present for more than 6 hours of post-operatory and may contribute to increase post-operatory bleeding.
Conditions
- Cardiac Surgery
- Cardiopulmonary Bypass
- Anticoagulation
Interventions
- DRUG
-
Heparin fixed doses
Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT \> 480 sec. Supplemental doses of 50mg of heparin if ACT \<480 sec during CPB. Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery.
- DRUG
-
PO continuous infusion of Protamine
25mg/hour in IV continuous infusion during first 6 PO hours
- DRUG
-
Heparin and protamine titration
Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB. Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve.
Sponsors & Collaborators
-
Instituto de Cardiologia do Rio Grande do Sul
collaborator OTHER -
Fundação Universitária de Cardiologia (University Foundation of Cardiology)
collaborator UNKNOWN -
SANE-Society of Anesthesiology
lead OTHER
Principal Investigators
-
Maria B Chuquer, M. D. · SANE-Society of Anesthesiology
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Primary Completion
- 2010-03-31
- Completion
- 2010-11-30
Countries
- Brazil
Study Locations
More Related Trials
-
Systematic Evaluation of Protamine Doze in Cardiac Surgery
NCT03787641 ·Status: UNKNOWN ·Phase: NA
-
Thrombin Generation During Cardiopulmonary Bypass With Titrated Versus Conventional Anticoagulation Management.
NCT03347201 ·Status: COMPLETED ·Phase: NA
-
Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients
NCT01574105 ·Status: COMPLETED
-
Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass
NCT00587444 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass
NCT01072955 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Sodium Heparin
NCT00894985 ·Status: COMPLETED ·Phase: PHASE3
-
Anticoagulation Management in Complex Cardiac Surgery
NCT05944107 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Sodium Heparin in Patients
NCT00894959 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients
NCT00894673 ·Status: COMPLETED ·Phase: PHASE3
-
Postoperative Use Of Pump Blood İn Cardiopulmonary Bypass Surgery
NCT06824753 ·Status: COMPLETED ·Phase: NA
-
Heparin Management During Cardiopulmonary Bypass in Children
NCT00146653 ·Status: COMPLETED
-
Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
NCT00420667 ·Status: COMPLETED ·Phase: NA
-
Management of Bleeding Following Cardiopulmonary Bypass
NCT00672516 ·Status: COMPLETED
-
Postural Mobilization Compared to Noradrenaline Only in Off-Pump CABG Surgery
NCT07163858 ·Status: RECRUITING ·Phase: NA
-
Haemostatic Markers in Cardiopulmonary Bypass
NCT03861286 ·Status: COMPLETED
-
Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery
NCT03302195 ·Status: RECRUITING ·Phase: NA
-
Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery
NCT00854217 ·Status: COMPLETED ·Phase: NA
-
Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding
NCT00188747 ·Status: COMPLETED ·Phase: PHASE4
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665 ·Status: RECRUITING ·Phase: PHASE3
-
Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation
NCT01078818 ·Status: COMPLETED ·Phase: PHASE4
-
Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.
NCT00405093 ·Status: COMPLETED
-
Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
NCT00823082 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Sodium Heparin (Eurofarma)
NCT00894829 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass
NCT02037555 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Heparinization Due to LBW
NCT03113708 ·Status: UNKNOWN ·Phase: PHASE4